ArticleAmerican journal of translational research2026
Analysis of the effectiveness of the myocardial work index in the assessment of cancer therapy-related cardiac dysfunction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation between myocardial global work index (GWI) and cancer therapy-related cardiac dysfunction (CTRCD) during chemotherapy for patients with thoracic tumors.
methodsA retrospective analysis was conducted on 87 patients with thoracic tumors who underwent chemotherapy at The Third Hospital of Hebei Medical University from April 2022 to June 2023. Among them, 37 patients who developed CTRCD during chemotherapy were assigned to the research group, and the remaining 50 patients without CTRCD were assigned to the control group. Myocardial GWI was compared between the two groups at three time points: before chemotherapy (T0), during chemotherapy cycle 3 (T1), and upon completion of chemotherapy (T2). The predictive value of myocardial GWI at T0 and T1 for CTRCD was analyzed. Patients were followed up for prognosis, and the relationship between myocardial GWI at T2 and the recovery from CTRCD was evaluated. Additionally, the correlation between myocardial GWI and Creatine Kinase-MB (CK-MB) and cardiac troponin T (cTnT) at T0-T2 was analyzed.
resultsThe myocardial GWI in the research group was lower than that in the control group at T0-T2 (
conclusionMyocardial GWI is a reliable predictor for the occurrence of CTRCD during chemotherapy in patients with thoracic tumors, providing valuable clinical insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.